Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Status:
Completed
Trial end date:
2014-06-24
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%)
was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or
Junctional non-Herlitz Epidermolysis Bullosa (EB).